New drug combo shows promise in early trial for advanced cervical and vaginal cancers

NCT ID NCT02595879

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 28 times

Summary

This early-phase study tested an oral drug called triapine added to standard chemoradiation (cisplatin and radiation) for people with advanced cervical or vaginal cancer. The goal was to find the safest dose and check how well the body absorbs the drug. 21 participants were enrolled. The study is active but no longer recruiting, and results will help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVA CERVICAL CANCER AJCC V6 AND V7 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Keck Medical Center of USC Pasadena

    Pasadena, California, 91105, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, 35233, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Kansas Clinical Research Center

    Fairway, Kansas, 66205, United States

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas, 66211, United States

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas, 66205, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, 48334, United States

Conditions

Explore the condition pages connected to this study.